Background
Case presentation
Clinical summary
Our values | Normal range | |
---|---|---|
Hb | 12,2 g/dl | 14-18 g/dl |
RBC | 5,3 × 106/mm3 | 4,5-6 × 106/mm3 |
WBC | 6,6 × 103/mm3 | 4-8 × 103/mm3 |
Hematocrit | 45% | 40-52% |
MCV | 90 μm3 | 83-93 μm3 |
MCHC | 34 g/dl | 32-36 g/dl |
Platelet count | 225 × 103/mm3 | 150-350 × 103/mm3 |
AST | 10 UI/l | 0-35 UI/l |
ALT | 10 UI/l | 0-35 UI/l |
LDH | 552 U/l | 120-240 U/l |
Total protein | 8,6 g/dl | 6,5-8,0 g/dl |
Albumin | 42,3 g/l | 35,2-50,4 g/l |
β2-microglobulin | 5.2 mg/dL | 0,1-0,2 mg/dL |
Blood urea nitrogen | 32 mg/dl | 10-50 mg/dl |
Creatinine | 0,9 mg/dl | 0-1,3 mg/dl |
Blood glucose | 96 mg/dl | 70-110 mg/dl |
C-reactive protein | 35 mg/l | 0-5 mg/l |
ACE | 15 U/l | < 40 U/l |
IgA | 1150 mg/dl | 90-450 mg/dl |
IgG | 2245 mg/dl | 80-1800 mg/dl |
IgM | 135 mg/dl | 60-250 mg/dl |
Pathologic findings
Discussion
Author | Sex | Age | Type of renal lesion | Interval (months) | Treatment | Clinical outcome |
---|---|---|---|---|---|---|
Wood and Harkins [13] | M | 76 | Diffuse proliferative glomerulonephritis | 0 | Corticosteroid, cyclophosphamide | Dead for lymphoma |
Wood and Harkins [13] | M | 79 | Minimal change disease | 0 | Dialysis | Dead for renal failure |
Bhat et al [8] | F | 77 | Acute renal failure with Bence-Jones proteinuria | 4 | None | Dead for sepsis |
Platzer et al [11] | M | 64 | Renal failure | 0 | Prednisolone | CR |
Bello et al [15] | M | 61 | Fanconi syndrome | 0 | Hydrocortisone | CR |
Bignon et al [23] | M | 70 | Dysproteinaemia | 0 | n.a. | n.a. |
Yamazaki et al [26] | M | 72 | Endocapillary proliferative glomerulonephritis | 0 | Vincristine, prednisolone | Dead for alimentary tract bleeding |
Nakamoto et al [10] | M | 40 | Acute interstitial nephritis | 16 | Prednisolone, cyclophosphamide | At 60-month follow-up, no signs of relapse |
Duwaji et al [28] | M | 71 | Proliferative glomerulonephritis | 2 | CHOP regimen | Dead for sepsis |
Lim et al [33] | M | 33 | Amyloidosis | 12 | CHOP regimen | At 12-month follow-up, no signs of relapse |
Hamidou et al [12] | M | 56 | Vasculitis | 0 | CHOP regimen | Dead for renal failure |
De Samblanx et al [2] | M | 67 | Proliferative glomerulonephritis | 0 | CHOP regimen | At 12-month follow-up, no signs of relapse |
Goto et al [9] | M | 73 | Direct invasion by lymphoma | 0 | CHOP regimen | At 20-month follow-up, no signs of relapse |
Miura et al [7] | M | 70 | IgM-λ glomerular thrombi | 2 | CHOP regimen | At 3-month follow-up, no signs of relapse |
Tagashi et al [16] | M | 21 | Nephrotic syndrome | 0 | CHOP regimen | At 36-month follow-up, no signs of relapse |